Related Experiment Video
Updated: Aug 9, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
Splice variants of human cathepsin L mRNA show different expression rates
A Abudula1, W Rommerskirch, E Weber
1Institut für Biochemie 1, Klinikum der Friedrich-Schiller-Universität, Jena, Germany.
Abstract:
Human cathepsin L (hCATL) mRNA occurs in vivo in at least three splice variants. They differ in the length of exon 1, which comprises 278 nucleotides (hCATL-A), 188 nucleotides (hCATL-A2) and 132 nucleotides (hCATL-A3), respectively. We describe here the shortest variant for the first time. This form is predominant in all tissues and cells examined so far, including malignant tumors. We studied the expression rate of the three mRNA variants in order to explain why malignant kidney tumors show low cathepsin L activity despite of high mRNA levels. The variant hCATL-A3 showed the highest expression rate in vitro and in vivo. Based on these results, we suggest a cis-acting element on human cathepsin L mRNA which can be bound by a negative trans-acting regulator, thus leading to reduced expression rates.
Insights
Researchers identified a new, predominant human cathepsin L (hCATL) mRNA variant, hCATL-A3. This shortest variant shows the highest expression, potentially explaining low hCATL activity in kidney tumors despite high mRNA levels.
Area of Science:
- Molecular Biology
- Biochemistry
- Genetics
Background:
- Human cathepsin L (hCATL) is a cysteine protease implicated in various physiological and pathological processes.
- hCATL mRNA exists in multiple splice variants, differing in exon 1 length.
- The shortest variant, hCATL-A3, is newly described and found to be predominant.
Purpose of the Study:
- To characterize the novel, shortest hCATL mRNA splice variant (hCATL-A3).
- To investigate the expression rates of different hCATL mRNA variants.
- To elucidate the discrepancy between high hCATL mRNA levels and low hCATL activity in malignant kidney tumors.
Main Methods:
- Analysis of hCATL mRNA splice variants using molecular biology techniques.
- Quantification of hCATL mRNA variant expression in vitro and in vivo.
- Comparative analysis of expression levels across different tissues and tumor types.
Main Results:
- Three hCATL mRNA splice variants (hCATL-A, hCATL-A2, hCATL-A3) were identified, differing in exon 1 length.
- The shortest variant, hCATL-A3 (132 nucleotides), is predominant in all examined tissues and cells, including tumors.
- hCATL-A3 exhibited the highest expression rate both in vitro and in vivo.
- The predominant expression of hCATL-A3 may contribute to reduced hCATL activity in malignant kidney tumors.
Conclusions:
- The shortest hCATL mRNA variant, hCATL-A3, is the predominant form in human tissues and tumors.
- A cis-acting element on hCATL mRNA likely binds a negative trans-acting regulator, reducing hCATL expression.
- This regulatory mechanism may explain the paradox of high hCATL mRNA and low activity in kidney cancers.
Related Concept Videos
RNA Splicing
Gene Evolution - Fast or Slow?
In contrast, regions which code...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Leaky Scanning

